Charles River Laboratories International, Inc. (NYSE:CRL) Stake Reduced by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 25,163 shares of the medical research company’s stock after selling 678 shares during the period. Cullen Frost Bankers Inc.’s holdings in Charles River Laboratories International were worth $5,948,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. abrdn plc increased its stake in shares of Charles River Laboratories International by 872.0% in the fourth quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after purchasing an additional 109,275 shares during the period. Regency Capital Management Inc. DE acquired a new stake in Charles River Laboratories International in the 4th quarter valued at approximately $3,703,000. WCM Investment Management LLC bought a new stake in Charles River Laboratories International during the 4th quarter valued at $1,396,000. DekaBank Deutsche Girozentrale boosted its position in Charles River Laboratories International by 98.6% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after acquiring an additional 6,997 shares during the period. Finally, AMG National Trust Bank bought a new position in shares of Charles River Laboratories International in the third quarter worth $1,119,000. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares of the company’s stock, valued at approximately $5,685,431.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at $626,155.20. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock worth $3,693,663 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Performance

CRL opened at $235.34 on Thursday. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. The firm has a market cap of $12.12 billion, a PE ratio of 25.55, a P/E/G ratio of 1.83 and a beta of 1.44. The business has a fifty day simple moving average of $251.18 and a 200-day simple moving average of $225.24. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. Charles River Laboratories International’s revenue for the quarter was down 7.9% on a year-over-year basis. During the same quarter last year, the company posted $2.98 EPS. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CRL shares. JPMorgan Chase & Co. lifted their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Evercore ISI upped their price target on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. TheStreet upgraded shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Robert W. Baird boosted their target price on Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a report on Thursday, February 15th. Finally, Argus increased their price target on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average target price of $253.23.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).